BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)

Saved in:

Bibliographic Details
Published in:	Hematological oncology Vol. 35; no. S2; p. 67
Main Authors:	Chen, R., Gibb, A.L., Collins, G.P., Popat, R., El‐Sharkawi, D., Burton, C., Lewis, D., Miall, F.M., Forgie, A., Compagnoni, A., Andreola, G., Brar, S., Thall, A., Woolfson, A., Radford, J.
Format:	Journal Article
Language:	English
Published:	Chichester Wiley Subscription Services, Inc 01-06-2017
Subjects:	Hodgkin's lymphoma Immunotherapy Lymphoma Monoclonal antibodies PD-1 protein PD-L1 protein Targeted cancer therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
ISSN:	0278-0232 1099-1069
DOI:	10.1002/hon.2437_54